Increased Anti-tumor Effect by a Combination of HSV Thymidine Kinase Suicide Gene Therapy and Interferon-γ/GM-CSF Cytokine Gene Therapy in CT26 Tumor Model by Yang, Sung Hyun et al.
INTRODUCTION
Popular strategies of cancer gene therapy have been to aug-
ment suicidal activity by introducing the Herpes simplex
virus thymidine kinase (HSVtk) gene through ganciclovir
(GCV) treatment (1-4) or to increase anti-tumor immune
response by transfer of some cytokine genes such as IL-2 (5,
6), IL-4 (7), IFN- (8), and granulocyte-macrophage colony-
stimulating factor (GM-CSF) (9). These studies have yielded
encouraging results, which have inspired investigators to
optimize the combinations of suicide gene with cytokine
genes or those of different cytokine genes to increase the anti-
tumor effect.
The HSVtk converts nucleoside analogues, such as GCV,
to monophosphate forms by phosphorylation. These are sub-
sequently modified to toxic triphosphates by endogenous
cellular enzymes and incorporated into nascent DNA, which
causes chain termination and cell death. With such an altera-
tion of GCV, neighboring cells that do not express the HSVtk
gene are killed in addition to the tumor cells expressing the
genes. As the phosphorylated GCV is unable to diffuse freely
across the plasma membrane, several mechanisms have been
suggested for this bystander killing effect. One of them is
the connexin gap junction-mediated intercellular transfer of
toxic phosphorylated GCV molecules (10, 11), although expla-
nation is not always applicable to different tumor types (12).
Some investigators have also reported that the bystander effect
is impaired, or even abrogated, when experiments are con-
ducted in immune compromised animals, which suggests
that an intact immune system is an important component
for obtaining a bystander effect (13). Within partly HSVtk
positive tumors, GCV treatment induces local leucocytes
infiltration and cytokine release (13, 14). 
Anti-tumor immune response is believed to be largely
dependent on major histocompatibility complex (MHC) class
I-restricted CD8+, cytolytic T-cells. Interferon- (IFN- ) is a
pleiotropic cytokine produced by activated T-lymphocytes.
It influences the immune response in several ways, largely
because it is a potent inducer of MHC class I antigens, which
may increase the antigen-presenting capacity of cells (15).
GM-CSF induces proliferation and differentiation of cells
committed to the granulocyte-macrophage lineage. It aug-
ments the antigen-presenting activity of macrophages and
activates dendritic cells (16). In addition, multiple cytokine
gene transfer showed additional or synergistic anti-tumor effects
but the tumor growth was not completely inhibited (17).
In clinical situation, cancer gene therapy will be first applied
to disseminated diseases or large bulky tumors that are refrac-
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Increased Anti-tumor Effect by a Combination of HSV Thymidine
Kinase Suicide Gene Therapy and Interferon- /GM-CSF Cytokine
Gene Therapy in CT26 Tumor Model
The potential therapeutic benefit of introducing IFN- and GM-CSF genes in com-
bination with the HSVtk suicide gene into subcutaneously implanted CT26 tumor
cells was compared with that from each treatment alone. Cells, unmodified or retro-
virally transduced with HSVtk or IFN- /GM-CSF genes, were inoculated subcuta-
neously into syngeneic BALB/c mice in various combinations. HSVtk gene, with
intraperitoneal ganciclovir treatment, reduced tumor volume by 81% at locally inoc-
ulated tumor sites (p<0.01) and by 25% at distantly inoculated tumor sites (p=0.052).
IFN- /GM-CSF genes showed a 56% tumor volume reduction at local tumor sites
(p<0.01) and 15% volume reduction at remote tumor sites, although this was not
statistically significant. The combination of HSVtk (with GCV) and IFN- /GM-CSF
genes showed an 81% volume reduction at local tumor sites (p<0.01) and a 43%
volume reduction at remote tumor sites (p<0.01). Thus, the combination of HSVtk
and IFN- /GM-CSF gene therapy produced greater therapeutic efficacy than either
treatment alone. 
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tory to current treatment modalities. However, current vec-
tor technologies do not enable transfer the therapeutic genes
into sufficient number of malignant cells to produce curative
effects within a solid tumor. Promise of viable treatment is
suggested by the numerous experimental suicide gene ther-
apies demonstrating a bystander killing effect of tumor cells.
As we have already demonstrated the effects of HSVtk and
GM-CSF combination gene therapy in a murine CT26 cancer
cell models (18), multiple gene transfer is now becoming an
important strategy in cancer gene therapy. In this study, exa-
mination was done whether combined HSVtk and IFN- /
GM-CSF gene therapy could show enhanced anti-tumor
effects over each treatment alone.
MATERIALS AND METHODS
Animal preparation
Six- to eight-week-old male syngeneic BALB/c mice from
which CT26 cells, an N-nitroso-N-methylurethane (NNMU)-
induced undifferentiated colon carcinoma line, originated
were purchased from a commercial vender (SLC Inc, Japan).
All animal protocols were performed according to the guide-
lines of the Chungbuk National University animal facilities
and NIH. Mice were allowed access to food and water ad libi-
tum for the duration of the experiment. 
Cell lines
CT26 cells, and PA317, PE501 and NIH 3T3 cells were
routinely maintained with DMEM (high glucose; Gibco BRL,
U.S.A.) containing 10% fetal bovine serum (heat inactivat-
ed), 100 U/mL of penicillin-streptomycin and 2 mM gluta-
mine under a 5% CO2-humidified air atmosphere at 37℃.
Vector preparation and transduction
All retroviral vectors were cloned using standard techniques.
The HSVtk expressing LtkSP vector was cloned as previously
described (18). The INF- expressing L SN vector was con-
structed by cloning the INF- cDNA into the HpaI site of
LXSN, provided by Professor William RA Osborne (Depart-
ment of Pediatrics, University of Washington, Seattle, WA,
U.S.A.). The GM-CSF expressing LNFGM vector was con-
structed by cloning the GM-CSF cDNA into the BamHI site
of LNFX. The INF- and GM-CSF co-expressing L FGMEN
vector was constructed as follows. A 975-base pair DNA frag-
ment encoding FGM portion of LNFGM vector was obtained
by digestion with restriction enzyme ClaI and fused with a
unique site of LAEN to construct LAFGMEN. Then the LA
part of LAFGMEN was replaced by the L part of L SN by
digestion with the restriction enzymes SacII and BamHI to
clone the final construct L FGMEN. 
The methods used to generate retroviral packaging cell
lines minimizing the formation of replication-competent retro-
virus, and to produce high-titer amphotropic vectors involv-
ing selection, dilution cloning, and screening, were as previ-
ously described (19).
The parental CT26 cells were transduced by each retrovirus
using amphotropic retroviral packaging cell line (PA317) as
previously described (19). CT26/TK cells were established by
the addition of 1  g/mL of puromycin for LtkSP, and CT26/
IFN, CT26/GM and CT26/ IFN-GM were also established
by selection with 1 mg/mL G418 for L SN, LNFGM and
L FGMEN, respectively. Cells were subcultured and grown
thereafter in appropriate selection containing media. 
IFN- and GM-CSF assay
Supernatants from 2×106 semiconfluent cells in a 6 cm
plate of CT26/ IFN, CT26/GM and CT26/ IFN-GM were
collected after 48 hr and assayed for mouse IFN- and GM-
CSF using an ELISA kit (Endogen, Boston, MA, U.S.A.).
Flow cytometry
Quantitative analysis of MHC expression on cell surface
was performed using a fluorescently activated cell sorter (FACS;
Epics XL-MCL, Coulter, Miami, FL, U.S.A.). Cells were
scraped from tissue culture plates using a rubber policeman
and incubated with murine anti-H-2KdDd monoclonal anti-
body for 30 min at 4℃. After being washed, the cells were
incubated with fluorescein isothiocyanate-conjugated goat
anti-mouse IgG antibodies at 4℃for 30 min, fixed with 1%
paraformaldehyde, and examined within one week using flow
cytometry. In all cases controls incubated with secondary anti-
bodyalone failed to show any significant nonspecific binding.
In vivo anti-tumor effect for locally and distantly inoculated
tumors
Four groups of mice (n=15 to 20), comprising GCV (Cy-
mevene, Roche products, Basel, Switzerland) treated or non-
treated, were subcutaneously implanted with tumor cells on
both flanks. The proportions of the cells implanted are listed
in Table 1. The mixture of CT26/TK and unmodified CT26
(each 5×105 cells of each in 100  L of phosphate-buffered
saline) was implanted on the left flank and unmodified CT26
GCV Right flank 
(5×10
5 cells)
Left flank (1×10
6 cells)
Control (-) CT26 50% CT26+50% CT26/TK
Suicide (+) CT26 50% CT26+50%CT26/TK
Cytokine (-) CT26 50% CT26/TK+50%CT26/ IFN-GM
Combined (+) CT26 50% CT26/TK+50%CT26/ IFN-GM
Table 1. In vivo experimental groups according to the compo-
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cells (5×105 cells) on the right flank as a control group (with-
out GCV) and suicidal gene therapy group (with GCV). In
cytokine (without GCV) and the combined gene therapy
group (with GCV), the mixture of CT26/TK and CT26/
IFN-GM (each 5×105 cells) was implanted on the left flank
and unmodified CT26 cells (5×105 cells) on the right flank.
The tumors were left to develop for 4 days before the mice
in each treatment group were intraperitoneally injected twice
daily with GCV at a dose of 50 mg/kg for 14 days (from D5
to D18). The size of each tumor was measured using calipers
and tumor volumes were calculated as: (longest diameter)×
(shortest diameter)2/2 (20).
Statistical analyses
The significance of difference between groups was tested
by a one-way ANOVA with the use of StatView 5.0 software
(SAS Institute Inc., Cary. NC, U.S.A.). If a probability value
of p<0.05 was obtained, the Tukey test was then used to
compare each individual group with its appropriate control.
RESULTS
Production of INF- and GM-CSF from transduced cell
lines
The concentrations of INF- from supernatants of CT26/
IFN and CT26/ IFN-GM cell lines were 630±34 and
716±65 pg/106 cells per day, respectively. There were no
significant differences in production rate of INF- in either
cell lines. The GM-CSF concentrations from CT26/GM and
CT26/ IFN-GM cell lines were very similar (18.1±2.1 vs.
16.3±1.5 pg/106 cells per day) (Table 2). This means that
the tricistronic retroviral vector cloned to co-express IFN-
and GM-CSF was working as well as single gene expression
vectors.
Increased expression of MHC class I antigen from CT26/
IFN and CT26/ IFN-GM cell lines 
Prior to transfection studies, we ascertained whether the
CT26 cells would express MHC class I antigen in response
to produced IFN- . Fig. 1 shows the expression of H-2KdDd
in CT26 cells as assessed by FACS using a specific murine
monoclonal antibody. The mean fluorescence intensities (MFI)
of unmodified CT26 and CT26/GM were 25 and 22.7, where-
as the MFI of CT26/ IFN and CT26/ IFN-GM were 41.1
and 45.5, respectively. This demonstrates an increase in MHC
class I antigen expression in only the IFN- transduced cell
lines. 
In vitro growth rate of various CT26 cell lines
We next determined if expressed IFN- or GM-CSF had
a cytostatic effect on CT26 cells. Unmodified CT26, CT26/
TK, CT26/ IFN-GM, 50% CT26+50% CT26/TK and
50% CT26+50% CT26/ IFN-GM (1×104 cells) were plated
and cultured for 8 days. The final cell number of those cell
lines were 6×106 for CT26, 5×106 for CT26/TK, 5.5×106
for CT26/ IFN-GM, 4.5×106 for 50% CT26+50% CT26/
TK and 4.4×106 for 50% CT26+50% CT26/ IFN-GM.
There were no differences in growth rate between the differ-
ent CT26 cell lines (Fig. 2).
In vivo local anti-tumor efficacy 
The tumor volumes at left flank of suicide group were sig-
nificantly lower than those of control group at day 11 (544
±196  L vs. 1,100±872 L,  p<0.05), day 15 (792±522
L vs. 2,624±1,667 L,  p<0.01) and day 18 (1,116±1,037
L vs. 5,980±2,768 L,  p<0.01) (Fig. 3A). There was an
81% volume reduction at day 18. 
The cytokine group at the left flank also showed signifi-
cantly lower mean tumor volume from day 11 (615±304
L, p<0.05; 1,042±441  L at day 15, p<0.01 and 2,609±
1,187  L at day 18, p<0.01 compared with each of the control
groups) (Fig. 3B) and a 56% volume reduction at day 18. 
The combined group also showed significant tumor vol-
Cell line  INF- (pg/10
6
cells per day)
GM-CSF (pg/10
6
cells per day)
CT26/ IFN 630±34 N.D
CT26/GM N.D 18.1±2.1
CT26/ IFN-GM 716±65 16.3±1.5
Table 2. Production rate of cytokines from transduced CT26 cell
lines
Results are expressed as mean±SD. N.D.; not detected.
These experiments were performed in triplicated. 
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ume reductions (394±187  L at day 11, p<0.01; 601±450
L at day 15, p<0.01 and 1,134±675  L at day 18, p<0.01
compared with each of control groups) (Fig. 3C) and an 81%
volume reduction at day 18. 
In vivo distant anti-tumor effect
The unmodified cells at the right flank of the suicide group
showed decreased tumor volume (25% volume reduction)
compared with that of the control group at day 18, although
the difference was not statistically significant (4,976±1,323
L vs. 6,690±3,469 L,  p=0.052, Fig. 4A). 
In the cytokine group, there was a 15% volume reduction
at day 18 compared with that of the control group, but it was
not statistically significant (5,637±1,964  L vs. 6,690±
3,469  L, Fig. 4B). 
The unmodified cells at the right flank of the combined
group showed significantly decreased tumor volumes from
day 15 compared with those of the control group (1,942±540
L vs. 2,961±1,648  L at day 15, p<0.05; 3,840±1,430
L vs. 6,690±3,469  L at day 18, p<0.01) (Fig. 4C) and a
43% volume reduction at day 18. This shows that the combi-
nation of suicidal and cytokine gene therapy has an additional
remote anti-tumor effect even though each treatment alone
had no significant remote effect. This means that a 25% vol-
ume reduction could result from the distant anti-tumor effect
of HSV-TK and an additional 18% volume decrease could
result from the effect of the cytokine gene therapy (Fig. 5).
DISCUSSION
Suicide gene therapy and cytokine gene therapy are promis-
ing approaches for cancer gene therapy (21-23). Various strate-
gies using HSVtk suicide gene therapy combined with local
delivery of cytokine genes have been explored in preclinical
Fig. 3. Tumor volumes of transduced CT26 cells at locally inoculated tumor. (A) control vs. suicide gene therapy, (B) control vs. cytokine
gene therapy, (C) control vs. combined gene therapy.
Differences were significant: *p<0.05, 
� p<0.01. Results were expressed as mean±SD. 
Fig. 2. In vitro growth of untransduced or transduced CT26 cells
used in animal study. There is no difference of growth rate in dif-
ferent cell lines.
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Fig. 4. Tumor volumes of untransduced CT26 cells at distantly inoculated tumor. (A) control vs. suicide gene therapy, (B) control vs. cytokine
gene therapy, (C) control vs. combined gene therapy.
Differences were significant: *p=0.052, 
� p<0.05, 
� p<0.01. Results were expressed as mean±SD. 
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models to target systemic neoplastic disease. Gene therapies
using various cytokine genes combined with HSVtk suicide
gene have been shown to increase anti-tumor effects leading
to prolongation of survival, partial protection against a sub-
sequent tumor challenge, and infiltration of immune cells
into the tumor (24-27). 
This study was undertaken to determine if cytokine gene
therapy using IFN- and GM-CSF in combination with
HSVtk suicide gene therapy could increase anti-tumor effects
at local and distant tumor sites. For this purpose, we cloned
retroviral vector expressing HSVtk and tricistronic retroviral
vector to co-express IFN- and GM-CSF. This tricistronic
vector expressed both cytokines as well as single gene expres-
sion vectors (Table 2).
Rodent tumor cells have been engineered to secrete cyto-
kines locally in an attempt to elicit immune responses against
the tumors (28). Secretion of IL-2, IL-4, IFN- or GM-CSF
by a variety of such tumor cells was shown to reduce the
tumorigenicity of these cells in syngeneic animals (17, 29,
30). In this context, the genes for GM-CSF and IFN- have
been studied most extensively to date. GM-CSF has poten-
tial as an important anti-neoplastic agent (16). Armstrong
et al. (9) reported that GM-CSF expression in the weakly
immunogenic murine B16-derived malignant melanoma cell
line HFH18 reduced tumorigenicity and induced protective
immunity in animals. In addition, they showed that GM-
CSF could induce an anti-tumor effect by recruiting dendritic
antigen-presenting cells. IFN- has also been reported to
induce a potent anti-tumor immune response, largely because
of the induction of MHC class I antigens. In this study, the
FACS results show that the MHC class I antigen was increased
in the IFN- -transduced cell lines. This result is compatible
with the finding of Webber and Rosenberg (15). 
In our study, HSVtk suicide gene therapy alone showed a
significant local bystander effect, in which an 80% volume
reduction was produced after inoculation of 50% CT26+
50% CT26/TK at the left flank compared with the control
group. This means that each HSVtk expressing cell could
inhibit approximately 0.6 unmodified neighboring cells in
vivo. This result is compatible with the finding of Lee et al.
(18) that two HSVtk cells could kill one neighbouring unmo-
dified cell in vivo. But, one HSVtk expressing cell in vitro
could kill two adjacent cells. Suicide gene treatment alone
also showed a 25% tumor volume reduction at distant tumor
sites, although the p-value was 0.052. The mechanism for
the distant bystander effect of HSVtk is not fully understood.
Although the transfer of toxic metabolites via gap junction
has a role, it is not possible to explain the distant anti-tumor
effect. It is known that HSVtk has a distant bystander effect
via an immunologic mechanism, in which the release of tumor
antigens by dying cells may induce systemic anti-tumor im-
munity (31, 32). 
Cytokine gene therapy alone also showed a local anti-tumor
effect, in which a 56% volume reduction was produced, but
this result was smaller than suicide gene treatment alone (56%
vs. 81%). This means that cytokine gene therapy can evoke
the local anti-tumor effect but it is weaker than suicidal gene
therapy. The distant anti-tumor effect was not shown in our
study design, which was to sacrifice animals at day 18. How-
ever, this finding is compatible with the report of Gansbacher
et al. (33) that IFN- producing CMS-5 cells on the left flank
did not inhibit the growth of unmodified CMS-5 cells on
the opposite flank. This also explains why the effect of IFN-
production by the tumor cells initially appeared to stimulate
a local rather than a systemic immune response but ultimately
led to a potent long-term protective immunity. Considering
the short-term duration of this study, an additional study
with a longer treatment period of cytokine gene therapy is
needed to show a distant anti-tumor effect. 
Finally, combined gene therapy showed significantly dec-
reased local and distant tumor volumes, in which an 81%
volume reduction at the locally inoculated tumor and a 43%
volume reduction at distantly inoculated tumor were obtained.
In addition, combined gene therapy showed earlier tumor
reduction from day 15 than did suicide treatment alone. This
means that combined gene therapy has an earlier and stronger
anti-tumor effect compared with each treatment alone. 
In summary, our study shows that cytokine gene therapy
using IFN- and GM-CSF genes in combination with HSVtk
suicide gene therapy could be an effective treatment modal-
ity for cancer gene therapy. 
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